Do the new signal transduction modulators have activity in vitro in tumor cells from ovarian carcinoma and lymphoma?
2005 (English)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE credits
Student thesis
Abstract [en]
During the last decades, chemotherapy with cytotoxic drugs has played a significant role in cancer therapy. It’s important to develop new anticancer drugs, and drug sensitivity testing in vitro can be used to find the right diagnosis for the newly developed substances.
The aim of this study was to investigate the cytotoxic activity of the new signal transduction modulators bortezomib, gefitinib and PKC412. The well-established substances cisplatin, cytarabine, doxorubicin and vincristin were investigated for comparison.
The activity of the cytotoxic drugs was analysed in human tumor samples from patients with ovarian carcinoma (n=16) and lymphoma (n=15) by using the Fluorometric Microculture Cytotoxicity Assay (FMCA). The testing of cellular drug resistance by FMCA was accomplished successfully in 33 out of the 34 samples (97%).
The results of this study indicated that the activity of cytotoxic drugs in tumor cells obtained from patients with ovarian carcinoma and lymphoma may be detected by the FMCA. It also suggested that bortezomib and gefitinib could represent promising agents for treatment of ovarian carcinoma and that PKC412 might be of less use for patients with this diagnose.
Place, publisher, year, edition, pages
2005. , p. 24
Keywords [en]
Anticancer drug development, ovarian carcinoma, lymphoma, FMCA, cytotoxic drugs, in vitro assay
National Category
Medical Bioscience
Identifiers
URN: urn:nbn:se:uu:diva-6158OAI: oai:DiVA.org:uu-6158DiVA, id: diva2:130394
Uppsok
lantbruk/veterinärmed./skogl. vetenskap
Supervisors
Examiners
2005-11-022005-11-02